IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC
RISKS TO HUMANS

VOLUME 66
SOME PHARMACEUTICAL DRUGS

1996
IARC
LYON
FRANCE
IARC MONOGRAPHS
ON THE
EVALUATION OF CARCINOGENIC RISKS TO HUMANS

Some Pharmaceutical Drugs

VOLUME 66

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon,

13–20 February 1996

1996
In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. The programme was subsequently expanded to include evaluations of carcinogenic risks associated with exposures to complex mixtures, life-style factors and biological agents, as well as those in specific occupations.

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for agents to which humans are known to be exposed and on specific exposure situations; to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields; and to indicate where additional research efforts are needed.

This project is supported by PHS Grant No. 5-U01 CA33193-14 awarded by the United States National Cancer Institute, Department of Health and Human Services. Additional support has been provided since 1986 by the European Commission.

©International Agency for Research on Cancer, 1996

IARC Library Cataloguing in Publication Data
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
(1996 : Lyon, France)

(IARC monographs on the evaluation of carcinogenic risks to humans ; 66)
3. Neoplasms – chemically induced
1. Series
ISBN 92 832 1266 5  (NLM Classification: W 1)
ISSN 0250-9555

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention.

All rights reserved. Application for rights of reproduction or translation, in part or in toto, should be made to the International Agency for Research on Cancer.

Distributed by IARCPress (Fax: +33 72 73 83 02; E-mail: press@iarc.fr)
and by the World Health Organization Distribution and Sales, CH-1211 Geneva 27
(Fax: +41 22 791 4857)

PRINTED IN THE UNITED KINGDOM